Retaglutide is a new dipeptidyl peptidase-4 (DPP-4) inhibitor class hypoglycemic drug. It performs exceptionally well in terms of hypoglycemic effect, tolerance, and patient compliance.
Mechanism of Action
DPP-4 Enzyme Inhibition: Prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing polypeptide (GIP) by the DPP-4 enzyme in the intestine and blood, effectively prolonging their active lifecycle.
Targeted Pancreatic Support: Promotes insulin secretion by pancreatic β cells without affecting the basal level of fasting insulin.
Glucagon Regulation: Reduces the secretion of glucagon by pancreatic α cells, enabling more effective control of postprandial blood sugar levels.
Key Clinical Advantages
Hypoglycemic Effect
Delivers superior control over postprandial blood sugar by maintaining hormone stability and enhancing natural insulin response.
High Tolerance
Designed to optimize therapeutic outcomes while maintaining a favorable safety and tolerability profile for long-term use.
Excellent Compliance
Supports consistent patient adherence through effective glycemic management without altering basal fasting insulin levels.
Frequently Asked Questions (FAQ)
Q
What class of drug is Retaglutide?
Retaglutide is a new dipeptidyl peptidase-4 (DPP-4) inhibitor class hypoglycemic drug.
Q
Which enzymes and peptides does Retaglutide target?
It prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing polypeptide (GIP) by targeting the DPP-4 enzyme in the intestine and blood.
Q
How does Retaglutide affect pancreatic β cells and insulin secretion?
It promotes insulin secretion by pancreatic β cells to manage blood sugar without affecting the basal level of fasting insulin.
Q
What role does Retaglutide play in managing postprandial blood sugar?
It reduces the secretion of glucagon by pancreatic α cells, allowing for more effective control of postprandial blood sugar levels.
Q
Does Retaglutide change fasting insulin levels?
No, Retaglutide works without affecting the basal level of fasting insulin.
Q
What are the overall clinical performance highlights of Retaglutide?
Retaglutide performs exceptionally well in terms of its hypoglycemic effect, patient tolerance, and overall compliance.
